Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Knight gains Canadian and Israeli rights to TherapeuticsMD's TX004HR and TX001HR for menopausal symptoms

Executive Summary

Knight Therapeutics Inc. licensed exclusive Canadian and Israeli commercialization rights to TherapeuticsMD Inc.'s hormone therapy candidates TX004HR (estradiol) and TX001HR (estradiol/progesterone) for menopausal symptoms.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register